06/10/2016 - 9:59am

Upsher-Smith’s Qudexy XR has gained tentative approval from the Food and Drug Administration as a preventative therapy for migraine headaches.

06/08/2016 - 12:23pm
The program, RespiPoints, is being undertaken in partnership with HealthPrize Technologies. 
06/07/2016 - 2:42pm

Under the partnership, Ultragenyx will initially receive an exclusive license for one of Takeda’s preclinical product candidates in a pre-determined field of use, along with the option to co-develop and co-commercialize the candidate in other therapeutic areas.

06/06/2016 - 12:33pm

The drug is indicated to treat hypertension to lower blood pressure, and the company said it is the first fixed-dose combination of a beta-blocker and an angiotensin II receptor blocker in the U.S.

06/01/2016 - 1:20pm
The topical steroid is indicated to treat mild to moderate plaque psoriasis in patients older than 18 years of age. 
06/01/2016 - 12:07pm
The trade name of the drug was initially Brintellix when it was approved in September 2013 and FDA approved a name change to minimize patient confusion over similarly named medication in early May. 
05/31/2016 - 2:32pm

Zinbryta is a once-daily self-administered injection indicated to treat relapsing forms of multiple sclerosis in patients who have had an inadequate response to two or more MS therapies. 

05/31/2016 - 11:40am

The new drug is indicated as a once-daily adjunctive treatment for Type 2 diabetes and works by increasing hormones that stimulate insulin production in the pancreas and that stimulate the liver to produce less glucose.

05/25/2016 - 1:57pm

In addition to naming a COO and EVP strategy, Gilead announced that its EVP commercial operations will be leaving the company to pursue other opportunities.